# Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

> **NCT00054405** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Recurrent Neuroblastoma

## Interventions

- **BIOLOGICAL:** recombinant interleukin-12
- **BIOLOGICAL:** aldesleukin

## Key facts

- **NCT ID:** NCT00054405
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-12
- **Primary completion:** 2009-05
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00054405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00054405, "Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00054405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*